A phase II study conducted in France suggests that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake may improve local disease control compared with standard radiotherapy in patients with inoperable stage III non-small cell lung cancer (NSCLC). The multicenter trial randomly assigned 158 patients to receive boosted radiotherapy or standard radiotherapy, after receiving induction platinum-based chemotherapy and chemoradiotherapy. Patients in the boosted radiotherapy group who showed FDG-PET residual uptake received a radiotherapy boost, resulting in a higher 15-month local control rate (77.6% vs. 71.2%) and longer median progression-free survival (22.3 months vs. 12.3 months) compared to the standard radiotherapy group. Adverse events were similar between the two groups. The researchers suggest that a randomized phase III evaluation of this FDG-PET-guided radiotherapy dose adaptation is warranted in patients with stage III NSCLC.
Thu, 22 Aug 2024 16:02:40 GMT | The ASCO Post